# Combination of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects

> **NCT03629067** · PHASE1 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 60 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** Treatment T
- **DRUG:** Treatment R

## Key facts

- **NCT ID:** NCT03629067
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-13
- **Primary completion:** 2018-11-29
- **Final completion:** 2018-12-27
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03629067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03629067, "Combination of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03629067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*